CRISPR Therapeutics (CRSP) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 7, 2026

Net selling: insiders sold $4.9M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$4.9M net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about CRSP filings

Are insiders buying or selling Crispr Therapeutics AG (CRSP) stock?

Net selling: insiders sold $4.9M and bought $0 of CRSP stock on the open market in the 90 days to Nov 7, 2026, according to SEC Form 4 filings. $1.5M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Kulkarni, Samarth (Chief Executive Officer), who sold $2.6M. The latest filing was on Oct 20, 2026.

Which members of Congress have traded CRSP recently?

None. No member of Congress disclosed a CRSP trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this CRSP smart-money data?

This summary uses filings available on Nov 7, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on CRSP

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $3.3M
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean long2 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about CRSP filings

Are insiders buying or selling Crispr Therapeutics AG (CRSP) stock?

Which members of Congress have traded CRSP recently?

None. No member of Congress disclosed a CRSP trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this CRSP smart-money data?

Funds

What funds are doing

3 moves · 6 mo

Buys/Adds$77.0MSells/Trims$23.2M

Buys/Adds (2)

DS
D.E. Shaw
Q2 2026 13F
$48.7M
bought
Signals like this: n=3228, 54% finished lower at D15, median -0.8% vs SPY -0.4%
SU
Susquehanna
Q1 2026 13F
$28.2M
bought

Sells/Trims (1)

SQ
Squarepoint
Q1 2026 13F
$23.2M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 2, 2026

Earnings came in 8.5% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 2, 2026

Period ending

Sep 30, 2026

Earnings per share

-$1.15-8.49% miss

-$1.06 expected

Revenue

$12.7M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 9, 2026, in 2 days

Estimates as of Nov 7, 2026

EPS expected

-$1.06

-$1.50 to -$0.46

Revenue expected

$16.6M

16 analysts

Last 30 days

0up1down

Analysts cutting estimates

Estimate drift

0.01

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 2, 2026	-$1.15est. -$1.06	-8.49%miss	$12.7MSEC filing	+1325.1%from $889.0K
Jun 30, 2026Reported Aug 3, 2026	-$0.94est. -$1.10	+14.55%beat	$10.2MSEC filing	+1041.4%from $892.0K
Mar 31, 2026Reported May 4, 2026	-$1.28est. -$1.23	-3.68%miss	$1.5MSEC filing	+68.6%from $865.0K
Dec 31, 2025Reported Feb 12, 2026	-$1.37est. -$1.23	-11.38%miss	$3.5M · FYSEC filing	No year-ago quarter
Sep 30, 2025Reported Nov 10, 2025	-$1.17est. -$1.29	+9.23%beat	$889.0KSEC filing	+47.7%from $602.0K
Jun 30, 2025Reported Aug 4, 2025	-$1.29est. -$1.40	+7.86%beat	$892.0KSEC filing	+72.5%from $517.0K
Mar 31, 2025Reported May 6, 2025	-$1.58est. -$1.28	-23.44%miss	$865.0KSEC filing	+71.6%from $504.0K
Dec 31, 2024Reported Feb 11, 2025	-$0.44est. -$1.19	+62.89%beat	$37.3M · FYSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $51.01
High: $51.21
Low: $47.76
Prev close: $51.78
52-wk high: $63.45
52-wk low: $44.12
Mkt cap: $4.71B
ROE: -25.6%
Fwd P/E: 23.4x
Beta: 1.90
P/S: 187.1x
P/B: 2.9x
Profit margin: +0.0%
Op margin: -934.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Forward P/E: 23.36
Market cap: $4.7B

Valuation

P/S187.13
P/B2.86

Quality

Operating margin-934.0%
ROE-25.6%
ROA-13.5%

Growth

Beta1.90

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

15 / 100

RSI 14

48balanced

20D volatility

55%annualized

52-week range

$48.56

$44.12$63.45

20D support

$47.36recent floor

20D resistance

$55.82recent ceiling

Returns

5D -10.5%20D -3.7%60D -10.1%

Price vs moving averages

SMA20 -4.4%SMA50 -9.2%SMA200 -8.0%

Volume pace

0.75xvs prior 20D

Smart money at a glance

Filings to Nov 7, 2026

Net selling: insiders sold $4.9M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$4.9M net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about CRSP filings

Are insiders buying or selling Crispr Therapeutics AG (CRSP) stock?

Which members of Congress have traded CRSP recently?

None. No member of Congress disclosed a CRSP trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this CRSP smart-money data?

13F: filed up to 45 days late.

Smart money on CRSP

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $3.3M
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean long2 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about CRSP filings

Are insiders buying or selling Crispr Therapeutics AG (CRSP) stock?

Which members of Congress have traded CRSP recently?

None. No member of Congress disclosed a CRSP trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this CRSP smart-money data?

Funds

What funds are doing

3 moves · 6 mo

Buys/Adds$77.0MSells/Trims$23.2M

Buys/Adds (2)

DS
D.E. Shaw
Q2 2026 13F
$48.7M
bought
Signals like this: n=3228, 54% finished lower at D15, median -0.8% vs SPY -0.4%
SU
Susquehanna
Q1 2026 13F
$28.2M
bought

Sells/Trims (1)

SQ
Squarepoint
Q1 2026 13F
$23.2M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 2, 2026

Earnings came in 8.5% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 2, 2026

Period ending

Sep 30, 2026

Earnings per share

-$1.15-8.49% miss

-$1.06 expected

Revenue

$12.7M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 9, 2026, in 2 days

Estimates as of Nov 7, 2026

EPS expected

-$1.06

-$1.50 to -$0.46

Revenue expected

$16.6M

16 analysts

Last 30 days

0up1down

Analysts cutting estimates

Estimate drift

0.01

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 2, 2026	-$1.15est. -$1.06	-8.49%miss	$12.7MSEC filing	+1325.1%from $889.0K
Jun 30, 2026Reported Aug 3, 2026	-$0.94est. -$1.10	+14.55%beat	$10.2MSEC filing	+1041.4%from $892.0K
Mar 31, 2026Reported May 4, 2026	-$1.28est. -$1.23	-3.68%miss	$1.5MSEC filing	+68.6%from $865.0K
Dec 31, 2025Reported Feb 12, 2026	-$1.37est. -$1.23	-11.38%miss	$3.5M · FYSEC filing	No year-ago quarter
Sep 30, 2025Reported Nov 10, 2025	-$1.17est. -$1.29	+9.23%beat	$889.0KSEC filing	+47.7%from $602.0K
Jun 30, 2025Reported Aug 4, 2025	-$1.29est. -$1.40	+7.86%beat	$892.0KSEC filing	+72.5%from $517.0K
Mar 31, 2025Reported May 6, 2025	-$1.58est. -$1.28	-23.44%miss	$865.0KSEC filing	+71.6%from $504.0K
Dec 31, 2024Reported Feb 11, 2025	-$0.44est. -$1.19	+62.89%beat	$37.3M · FYSEC filing	No year-ago quarter

Open: $51.01
High: $51.21
Low: $47.76
Prev close: $51.78
52-wk high: $63.45
52-wk low: $44.12
Mkt cap: $4.71B
ROE: -25.6%
Fwd P/E: 23.4x
Beta: 1.90
P/S: 187.1x
P/B: 2.9x
Profit margin: +0.0%
Op margin: -934.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Forward P/E: 23.36
Market cap: $4.7B

Valuation

P/S187.13
P/B2.86

Quality

Operating margin-934.0%
ROE-25.6%
ROA-13.5%

Growth

Beta1.90

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

15 / 100

RSI 14

48balanced

20D volatility

55%annualized

52-week range

$48.56

$44.12$63.45

20D support

$47.36recent floor

20D resistance

$55.82recent ceiling

Returns

5D -10.5%20D -3.7%60D -10.1%

Price vs moving averages

SMA20 -4.4%SMA50 -9.2%SMA200 -8.0%

Volume pace

0.75xvs prior 20D

Crispr Therapeutics AG

Smart money at a glance

What do analysts expect?

Questions about CRSP filings

Smart money on CRSP

Questions about CRSP filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 8.5% below what analysts expected.

Estimated report: Nov 9, 2026, in 2 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Crispr Therapeutics AG

Smart money at a glance

What do analysts expect?

Questions about CRSP filings

Smart money on CRSP

Questions about CRSP filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 8.5% below what analysts expected.

Estimated report: Nov 9, 2026, in 2 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Crispr Therapeutics AG

Overview

Questions about CRSP filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Crispr Therapeutics AG

Overview

Questions about CRSP filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.